How genetics might shape responses to obesity medicines
A review explores genetic influences on obesity drug response, including indirect effects through other medicines, but reports no estimate of benefit from genetic testing.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review suggests that genetic differences could influence how people respond to GLP-1 receptor agonists, including through the handling of medicines taken alongside them. Its abstract offers a biological rationale for personalized care, but does not report whether testing genes or tailoring treatment actually improved weight loss, safety, or other patient outcomes.
The abstract gives no study count, effect estimates, or assessment of evidence quality. It therefore cannot show how strong the proposed genetic influences are or whether testing improves care.
Different routes of influence
The authors distinguish direct drug breakdown from indirect influences. They describe these obesity medicines as mainly broken down by enzymes that digest proteins, while genetic differences can also affect receptor signaling and responses to treatment.
Why other medicines matter
CYP2D6 is discussed chiefly because its genetic variants alter the metabolism of other medicines, including antidepressants and beta-blockers. The proposed connection to obesity treatment therefore involves concurrent medicines, rather than direct breakdown of the obesity drug.
The original publication
Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management.
Jayathilaka NS, Weththasinghe AV, Ganamurali N et al.
Clin Pharmacol Drug Dev · 2026
- PubMed ID
- 41238444
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.